Pfizer and Celltrion have announced new data for their Remicade biosimilar Inflectra that shows that the drug is comparable in safety and efficacy in a recent Phase 3 trial treating Crohns disease. Remicade was worth sales of $5.76 billion to Johnson &...
↧